Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Variations in tissue selectivity amongst insulin secretagogues: a systematic review.

Abdelmoneim AS, Hasenbank SE, Seubert JM, Brocks DR, Light PE, Simpson SH.

Diabetes Obes Metab. 2012 Feb;14(2):130-8. doi: 10.1111/j.1463-1326.2011.01496.x. Epub 2011 Nov 3. Review.

PMID:
21923736
2.

The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.

Sunaga Y, Gonoi T, Shibasaki T, Ichikawa K, Kusama H, Yano H, Seino S.

Eur J Pharmacol. 2001 Nov 9;431(1):119-25.

PMID:
11716850
3.

Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions.

Gribble FM, Reimann F.

J Diabetes Complications. 2003 Mar-Apr;17(2 Suppl):11-5. Review.

PMID:
12623163
4.

Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.

Hu S, Wang S, Fanelli B, Bell PA, Dunning BE, Geisse S, Schmitz R, Boettcher BR.

J Pharmacol Exp Ther. 2000 May;293(2):444-52.

5.

Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.

Hansen AM, Christensen IT, Hansen JB, Carr RD, Ashcroft FM, Wahl P.

Diabetes. 2002 Sep;51(9):2789-95.

6.

Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure.

Dörschner H, Brekardin E, Uhde I, Schwanstecher C, Schwanstecher M.

Mol Pharmacol. 1999 Jun;55(6):1060-6.

7.

Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.

Gribble FM, Tucker SJ, Seino S, Ashcroft FM.

Diabetes. 1998 Sep;47(9):1412-8.

PMID:
9726229
8.

Taurine block of cloned ATP-sensitive K+ channels with different sulfonylurea receptor subunits expressed in Xenopus laevis oocytes.

Lim JG, Lee HY, Yun JE, Kim SP, Park JW, Suh SI, Jang BC, Cho CH, Bae JH, Kim SS, Han J, Park MJ, Song DK.

Biochem Pharmacol. 2004 Sep 1;68(5):901-10.

PMID:
15294453
9.

Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K(ATP) channels.

Chachin M, Yamada M, Fujita A, Matsuoka T, Matsushita K, Kurachi Y.

J Pharmacol Exp Ther. 2003 Mar;304(3):1025-32.

10.

Different binding properties and affinities for ATP and ADP among sulfonylurea receptor subtypes, SUR1, SUR2A, and SUR2B.

Matsuo M, Tanabe K, Kioka N, Amachi T, Ueda K.

J Biol Chem. 2000 Sep 15;275(37):28757-63.

11.

Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands.

Winkler M, Stephan D, Bieger S, Kühner P, Wolff F, Quast U.

J Pharmacol Exp Ther. 2007 Aug;322(2):701-8. Epub 2007 May 10.

12.

Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmachological properties and tissue selectivity.

Nagashima K, Takahashi A, Ikeda H, Hamasaki A, Kuwamura N, Yamada Y, Seino Y.

Diabetes Res Clin Pract. 2004 Dec;66 Suppl 1:S75-8. Review.

PMID:
15563985
13.

Potassium channel openers require ATP to bind to and act through sulfonylurea receptors.

Schwanstecher M, Sieverding C, Dörschner H, Gross I, Aguilar-Bryan L, Schwanstecher C, Bryan J.

EMBO J. 1998 Oct 1;17(19):5529-35.

14.

Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.

Dabrowski M, Wahl P, Holmes WE, Ashcroft FM.

Diabetologia. 2001 Jun;44(6):747-56.

PMID:
11440368
15.

Treating diabetes today: a matter of selectivity of sulphonylureas.

Seino S, Takahashi H, Takahashi T, Shibasaki T.

Diabetes Obes Metab. 2012 Jan;14 Suppl 1:9-13. doi: 10.1111/j.1463-1326.2011.01507.x. Review.

PMID:
22118705
16.

Sulfonylurea receptors type 1 and 2A randomly assemble to form heteromeric KATP channels of mixed subunit composition.

Chan KW, Wheeler A, Csanády L.

J Gen Physiol. 2008 Jan;131(1):43-58. Epub 2007 Dec 17.

17.
18.

Identification of the high-affinity tolbutamide site on the SUR1 subunit of the K(ATP) channel.

Ashfield R, Gribble FM, Ashcroft SJ, Ashcroft FM.

Diabetes. 1999 Jun;48(6):1341-7.

PMID:
10342826
19.

Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A.

Lang VY, Fatehi M, Light PE.

Pharmacogenet Genomics. 2012 Mar;22(3):206-14. doi: 10.1097/FPC.0b013e32835001e7.

PMID:
22209866
20.

Supplemental Content

Support Center